Skip to main content
Fig. 5 | Acta Neuropathologica Communications

Fig. 5

From: Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition

Fig. 5

Cellular and molecular responses to tepotinib, irradiation or their combination. A,B. Syngeneic mice were intracranially implanted with SMA-560 glioma cells and treated daily with 100 mg/kg tepotinib from day 6 on or solvent, or with a single dose of 12 Gy on day 7, or in combination. A. Brains from three pre-randomized animals per group were stained for H&E (upper row), Ki-67 (middle row) or CD31 (lower row). Sections were counterstained with hematoxylin (blue). Quantification of immunoreactivity is shown in the right panels (n = 3, * p < 0.05, t-test, compared with control). B. Tumor lysates pooled from 2 prerandomized animals per group were analysed by proteome profiler array. Fold-changes indicate down-regulation (left) or up-regulation (right) versus control tumors. A difference down or up of twofold versus control was used as cut-off to assign a target to any group. Not all groups shown in Table S1 are included here

Back to article page